Why Cardiol Therapeutics Inc.’s (CRDL) Stock Is Down 5.03%
As of Tuesday, September 15, Cardiol Therapeutics Inc.’s CRDL share price has dipped by 5.03%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
Commentary & Analysis
Why Cardiol Therapeutics Inc.’s (CRDL) Stock Is Down 6.07%
As of Friday, August 28, Cardiol Therapeutics Inc.’s CRDL share price has dipped by 6.07%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Cardiol Therapeutics Inc.’s (CRDL) Stock Is Up 6.25%
As of Wednesday, August 26, Cardiol Therapeutics Inc.’s CRDL share price has surged by 6.25%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Cardiol Therapeutics Inc.’s (CRDL) Stock Is Up 11.25%
As of Wednesday, August 26, Cardiol Therapeutics Inc.’s CRDL share price has surged by 11.25%, which has investors questioning if this is right time to sell.Tudor Pop
Why Cardiol Therapeutics Inc.’s (CRDL) Stock Is Up 7.26%
As of Tuesday, August 25, Cardiol Therapeutics Inc.’s CRDL share price has surged by 7.26%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | CRDL | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $217.7 | $586.4 | 28% |
|
| Shares Out (Mil) | 80.9 | 43.1 | 58% |
|
| Institutional Ownership | 79.8% | 83.7% | 48% |
|
| Float (Mil) | 92.0 | 45.1 | 59% |
|
| Beta | 0.47 | 0.73 | 27% |
|
| Avg Daily Volume (000s) | 1,301 | 331 | 74% |
|
| Price Change (52-week) |
73.6% | 63.2% | 89% |
|
| Growth | CRDL | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | (8.8%) | (1.4%) | 30% |
|
| EPS (5yr) | 12.2% | 15.1% | 51 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (19.7%) | (15.0%) | 34% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 4 | |
| Current EPS | ($0.054) | ($0.224) | ($0.237) | |
| Month Ago EPS | ($0.057) | ($0.232) | ($0.217) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.074) | ($0.257) | ($0.200) | |
| Year/Year Chg | 45.9% | (21.1%) | (84.2%) | |
| Financials | CRDL | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $317 | na |
|
| Net Income (TTM) (Mil) | ($24) | ($11) | 22% |
|
| EPS (TTM) | ($0.236) | ($0.600) | 32% |
|
| Operating Cash Flow (TTM) (Mil) | ($17) | ($6) | 16% |
|
| Net Cash Flow (TTM) (Mil) | $6 | $5 | 53% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 0% |
|
| Enterprise Value (Q1) (Mil) | $194 | $515 | 26% |
|
| Valuation | CRDL | Industry Median |
Percentile (All Stocks) |
|
| P/B | 12.50 | 2.51 | 92% |
|
| P/E | na | 17.1 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | CRDL | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 69.4% | na |
|
| Net Margin | na | 2.5% | na |
|
| ROA | (136.0%) | (22.4%) | 4% |
|
| ROE | (187.6%) | (21.8%) | 4% |
|
| Liabilities to Assets | 18.2% | 32.4% | 12% |
|
| F-Score | 4 | 3 | 33% |
|
Cardiol Therapeutics Inc. did not pass any screens on 9/18/2026.
